Monoclonal antibodies against HER2 epitope
First Claim
Patent Images
1. An isolated antibody which binds to human epidermal growth factor receptor 2 (HER2), comprising a VH region and a VL region selected from the group consisting of:
- a) a VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs;
2, 3 and 4, respectively; and
a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO;
6, GAS, and SEQ ID NO;
7, respectively;
b) a VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs;
9, 10 and 11, respectively; and
a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO;
13, DAS, and SEQ ID NO;
14, respectively;
c) a VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs;
16, 17 and 18, respectively; and
a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO;
20, GAS, and SEQ ID NO;
21, respectively;
d) a VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs;
23, 24 and 25, respectively; and
a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO;
27, GAS, and SEQ ID NO;
28, respectively;
e) a VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs;
30, 31 and 32, respectively; and
a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO;
34, GAS, and SEQ ID NO;
35, respectively; and
f) a VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs;
37, 38 and 39, respectively; and
a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO;
41, GAS, and SEQ ID NO;
42, respectively.
1 Assignment
0 Petitions
Accused Products
Abstract
Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
22 Citations
43 Claims
-
1. An isolated antibody which binds to human epidermal growth factor receptor 2 (HER2), comprising a VH region and a VL region selected from the group consisting of:
-
a) a VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs;
2, 3 and 4, respectively; and
a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO;
6, GAS, and SEQ ID NO;
7, respectively;b) a VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs;
9, 10 and 11, respectively; and
a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO;
13, DAS, and SEQ ID NO;
14, respectively;c) a VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs;
16, 17 and 18, respectively; and
a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO;
20, GAS, and SEQ ID NO;
21, respectively;d) a VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs;
23, 24 and 25, respectively; and
a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO;
27, GAS, and SEQ ID NO;
28, respectively;e) a VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs;
30, 31 and 32, respectively; and
a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO;
34, GAS, and SEQ ID NO;
35, respectively; andf) a VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs;
37, 38 and 39, respectively; and
a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO;
41, GAS, and SEQ ID NO;
42, respectively. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)
-
Specification